Biosimilar Interchangeability May Be Losing Luster As Approval Goal
Pricing now may mean more to payers than whether the product is interchangeable.
You may also be interested in...
With EpiPen injector patent-protected and patients accustomed to its use, finding a substitutable generic device may prove difficult.
Third biosimilar approved in US brings another iteration of FDA thinking on labeling and naming; etanercept-szzs, which references Amgen's Enbrel, suggests agency might be backtracking on its suffix policy.
It's the only addition to the agency's 2016 agenda.